Active Biotech
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
ACTI | ST
Overview
Corporate Details
- ISIN(s):
- SE0001137985 (+2 more)
- LEI:
- 549300OJ44CLMRU8YE43
- Country:
- Sweden
- Address:
- Scheelevägen 22, 223 63 Lund
Description
Active Biotech is a biotechnology company that develops pharmaceuticals for specialist indications with high medical need, focusing on oncology and inflammatory eye disorders. The company leverages its knowledge of the immune system to advance its clinical pipeline. Its portfolio includes fully-owned projects such as tasquinimod for hematological cancers, including multiple myeloma and myelofibrosis, and laquinimod, developed as eye drops for non-infectious uveitis. Additionally, the company has licensed projects, including naptumomab, which is being developed in partnership with NeoTX for the treatment of solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-10 08:30 |
First subject dosed in phase I clinical study with eye-drop formulation of laqu…
|
English | PDF • 68.9 KB | ||
| 2021-11-30 15:00 |
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Activ…
|
English | PDF • 66.8 KB | ||
| 2021-11-30 15:00 |
Data som visar att naptumomab estafenatox förstärker CAR-T-cellers effekt prese…
|
Swedish | PDF • 68.7 KB | ||
| 2021-11-09 14:00 |
Active Biotechs partner NeoTX presenterar vid det årliga mötet i Society for Im…
|
Swedish | PDF • 71.0 KB | ||
| 2021-11-09 14:00 |
Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of C…
|
English | PDF • 69.1 KB | ||
| 2021-11-04 14:00 |
New preclinical data on tasquinimod will be presented at the annual meeting of …
|
English | PDF • 69.5 KB | ||
| 2021-11-04 14:00 |
Nya prekliniska data kring tasquinimod kommer att presenteras på det årliga möt…
|
Swedish | PDF • 71.3 KB | ||
| 2021-11-04 08:30 | Swedish | PDF • 500.0 KB | |||
| 2021-11-04 08:30 | English | PDF • 493.6 KB | |||
| 2021-10-20 07:00 | Swedish | PDF • 69.2 KB | |||
| 2021-10-20 07:00 |
Active Biotech and NeoTX today announce that the first patient has been enrolle…
|
English | PDF • 68.2 KB | ||
| 2021-10-03 21:30 |
Active Biotech: Tasquinimod clinical development in multiple myeloma advances …
|
English | PDF • 71.9 KB | ||
| 2021-10-03 21:30 |
Active Biotech: Utvecklingen av tasquinimod i multipelt myelom fortsätter i kom…
|
Swedish | PDF • 73.8 KB | ||
| 2021-08-05 08:30 | Swedish | PDF • 465.4 KB | |||
| 2021-08-05 08:30 | English | PDF • 462.5 KB |
Automate Your Workflow. Get a real-time feed of all Active Biotech filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Active Biotech
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Active Biotech via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Peter Thelin | Other | Other | 164,638,960 | 8,231,948.00 SEK |
| 2024-11-15 | Hans Kolam | Other | Other | 19,800 | 990.00 SEK |
| 2022-09-05 | Aleksandar Danilovski | Other | Buy | 26,672 | 26,672.00 SEK |
| 2022-04-22 | Helen Tuvesson Andersson | Other | Buy | 2,665 | 3,102.86 SEK |
| 2022-04-21 | Helen Tuvesson Andersson | Other | Buy | 37,335 | 41,767.60 SEK |
| 2021-06-17 | Aleksandar Danilovski | Other | Buy | 40,000 | 60,000.00 SEK |
| 2021-06-01 | Michael Shalmi | Other | Buy | 175,000 | 259,437.50 SEK |
| 2021-04-27 | Helen Tuvesson Andersson | Other | Buy | 10,411 | 16,657.60 SEK |
| 2021-04-27 | Helena Eriksson | Other | Buy | 10,000 | 14,460.00 SEK |
| 2021-04-27 | Helen Tuvesson Andersson | Other | Buy | 1,041 | 1,665.60 SEK |
Peer Companies
